{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:54:46Z","timestamp":1790142886458,"version":"4.0.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["45\/36\/2022\/-DDI\/BMS"],"award-info":[{"award-number":["45\/36\/2022\/-DDI\/BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases Now"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.idnow.2025.105164","type":"journal-article","created":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T03:51:15Z","timestamp":1759636275000},"page":"105164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-life evaluation of intermittent triple antiretroviral therapy maintenance strategies"],"prefix":"10.1016","volume":"55","author":[{"given":"B","family":"HOELLINGER","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"REY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"KLEE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"CHENEAU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"MENOULOU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"LEMMET","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"GANTNER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2383-7415","authenticated-orcid":false,"given":"A","family":"URSENBACH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idnow.2025.105164_b0005","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/hiv.13542","article-title":"Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023","volume":"24","author":"Ambrosioni","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.idnow.2025.105164_b0010","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/S2352-3018(21)00300-3","article-title":"A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial","volume":"9","author":"Landman","year":"2022","journal-title":"Lancet HIV"},{"key":"10.1016\/j.idnow.2025.105164_b0015","unstructured":"Conseil national du sida et des h\u00e9patites virales [Internet]. 2024. Recommandations de prise en charge du VIH, des h\u00e9patites virales et des IST\u00a0: rapport d\u2019experts [updated September 12, 2025; cited January 2, 2025]. Available from: https:\/\/cns.sante.fr\/dossiers\/dossier-experts\/rapport-experts-2023\/."},{"key":"10.1016\/j.idnow.2025.105164_b0020","unstructured":"European AIDS Clinical Society [Internet]. 2024. EACS Guidelines 2024 [cited June 18, 2025]. Available from: https:\/\/eacs.sanfordguide.com."},{"key":"10.1016\/j.idnow.2025.105164_b0025","unstructured":"British HIV Association [Internet]. 2025. BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022 (2023 interim update) [cited June 18, 2025]. Available from: https:\/\/bhiva.org\/clinical-guideline\/hiv-1-treatment-guidelines\/,."},{"key":"10.1016\/j.idnow.2025.105164_b0030","unstructured":"Clinical Info HIV.gov [Internet]. 2025. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV - What\u2019s New in the Guidelines [cited May 19, 2025]. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new."},{"key":"10.1016\/j.idnow.2025.105164_b0035","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/jac\/dkx434","article-title":"Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial","volume":"73","author":"de Truchis","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2025.105164_b0040","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3390\/jpm13040583","article-title":"Intermittent bictegravir\/emtricitabine\/tenofovir alafenamide treatment maintains high level of viral suppression in virally suppressed people living with HIV","volume":"13","author":"Sellem","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.idnow.2025.105164_b0045","article-title":"Intermittent doravirine\/lamivudine\/tenofovir disoproxil fumarate (DOR\/3TC\/TDF) maintains a high level of viral suppression in virologically suppressed people living with HIV","volume":"53","author":"Palich","year":"2023","journal-title":"Infect Dis Now"},{"key":"10.1016\/j.idnow.2025.105164_b0050","unstructured":"Parienti JJ. Intermittent three-drug regimens (i-3DR) as maintenance ART: A meta-analysis including individual participant data. Abstract presented at; 2023 Dec 1; EACS 2023:419."},{"key":"10.1016\/j.idnow.2025.105164_b0055","article-title":"Five-days-on-two-days-off (FOTO) versus daily bictegravir\/emtricitabine\/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial","volume":"dkaf186","author":"Sun","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2025.105164_b0060","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1097\/QAD.0000000000004215","article-title":"Cost-effectiveness of a 4 days-a-week triple therapy in persons with HIV: an ancillary study of the QUATUOR trial","volume":"39","author":"Hejblum","year":"2025","journal-title":"AIDS"},{"key":"10.1016\/j.idnow.2025.105164_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010307","article-title":"A Randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda","volume":"5","author":"Reynolds","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.idnow.2025.105164_b0070","unstructured":"Landman R. ANRS 177 DUETTO randomized, open-label and multicentric trial evaluating the non-inferiority of maintenance antiretroviral dual therapy taken 4 consecutive days per week versus dual therapy 7\/7\u2009days per week. Abstract presented at; 2023 Dec 1; EACS 2023: 1096."},{"key":"10.1016\/j.idnow.2025.105164_b0075","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12981-024-00604-9","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine in virologically suppressed people with HIV-1 aged\u2009\u2265\u200950 years: week 48 pooled results from the TANGO and SALSA studies","volume":"21","author":"Walmsley","year":"2024","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.idnow.2025.105164_b0080","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/ciad020","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency Virus 1 type 1 infection: 152-Week results from ATLAS-2M, a randomized, open-label, phase 3b","volume":"76","author":"Overton","year":"2023","journal-title":"Noninferiority Study Clin Infect Dis"}],"container-title":["Infectious Diseases Now"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991925001435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991925001435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T17:12:23Z","timestamp":1768065143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666991925001435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2666991925001435"],"URL":"https:\/\/doi.org\/10.1016\/j.idnow.2025.105164","relation":{},"ISSN":["2666-9919"],"issn-type":[{"value":"2666-9919","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life evaluation of intermittent triple antiretroviral therapy maintenance strategies","name":"articletitle","label":"Article Title"},{"value":"Infectious Diseases Now","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idnow.2025.105164","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105164"}}